Trial Profile
Efficacy and safety of glycemic control in type 2 diabetes patients when switched to mitiglinide/voglibose fixed-dose combination therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2013
Price :
$35
*
At a glance
- Drugs Mitiglinide/voglibose (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Oct 2013 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 30 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 11 Apr 2012 New trial record